Сутент® (Sutent, SU11248) – новый мультитаргетный ингибитор ангиогенеза опухолей

1. Имянитов Е.Н. Ингибиторы циклооксигеназы-2 (коксибы): принцип действия и перспективы применения в онкологии. Фарматека. 2005; 18: 51–6.
2. Имянитов Е.Н. Эпидемиология и биология опухолей почки. Практич. онкол. 2005; 6 (3): 137–40.
3. Моисеенко В.М. Почему не улучшаются показатели общей выживаемости больных с диссеминированными солидными опухолями? Вопр. онкол. 2004; 50 (2): 149–56.
4. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005; 54: 53–61.
5. Blanke C. Role of COX-2 inhibitors in cancer therapy. Cancer Invest 2004; 22: 271–82.
6. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–86.
7. Broxterman HJ, Georgopapadakou NH. New cancer therapeutics: target-specific in, cytotoxics out? Drug Resist Updat 2004; 7: 79–87.
8. Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011–6.
9. Demetri G, van Oosterom A, Garrett C et al. Sunitinib malate (SU11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: update of a phase III trial. Eur J Cancer (Suppl.) 2005; 3: 203, abstr. 716.
10. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25–35.
11. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005; 41: 1109–16.
12. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004; 25: 536–42.
13. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275–88.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6.
15. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29 (6 Suppl. 16): 15–8.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
17. Imyanitov EN, Kuligina ESh, Belogubova EV et al. Mechanisms of lung cancer. Drug Discov, Today: Dis Mech 2005; 2: 213–23.
18. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423–36.
19. Kulke M, Lenz H, Meropol N et al. Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs). Eur J Cancer (Suppl.) 2005; 3: 204, abstr. 718.
20. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–37.
21. Miller KD, Burstein HJ, Elias AD et al. Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MBC) patients: preliminary results from a Phase II study. Eur J Cancer (Suppl.) 2005; 3: 113, abstr. 406.
22. Morgan JA, Demetri GD, Fletcher JA et al. Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248). Eur J Cancer (Suppl.) 2005; 3: 421, abstr. 1456.
23. Moss KG, Toner GC, Cherrington JM et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003; 307: 476–80.
24. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24.
25. O'Farrell AM, Foran JM, Fiedler W et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465–76.
26. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939–52.
27. Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004; 27: 599–605.
28. Soria JC, Fayette J, Armand JP. Molecular targeting: targeting angiogenesis in solid tumors. Ann Oncol 2004; 15 (Suppl. 4): iv223–7.
29. Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004; 40: 2377–82.
30. Tuma RS. Three molecularly targeted drugs tested in kidney cancer clinical trials. J Natl Cancer Inst 2004; 96: 1270–1.
31. Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115–24.